BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23453499)

  • 1. L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
    Cacoub P; Terrier B; Saadoun D
    Presse Med; 2013 Apr; 42(4 Pt 2):523-7. PubMed ID: 23453499
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Delluc A; Piette JC; Cacoub P
    Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of chronic hepatitis C].
    Schaffstein S; Rampini SK; Müllhaupt B
    Praxis (Bern 1994); 2014 Apr; 103(8):423-36. PubMed ID: 24713377
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of hepatitis C-mediated glomerular disease.
    Sandri AM; Elewa U; Poterucha JJ; Fervenza FC
    Nephron Clin Pract; 2011; 119(2):c121-9; discussion c129-30. PubMed ID: 21757949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia.
    Rego TC; Massumoto CM; Batista RS; Moura LH; Soares LM; Gomes AP
    Braz J Infect Dis; 2007 Feb; 11(1):174-5. PubMed ID: 17625752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acquired hemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with peginterferon α-2a].
    Martínez Pascual C; Antón Ródenas G; Ortiz Sánchez ML; Pons Miñano JA
    Med Clin (Barc); 2013 Sep; 141(5):228-9. PubMed ID: 23473306
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
    Mazzaro C; Zorat F; Caizzi M; Donada C; Di Gennaro G; Maso LD; Carniello G; Virgolini L; Tirelli U; Pozzato G
    J Hepatol; 2005 May; 42(5):632-8. PubMed ID: 15826710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
    Saadoun D; Resche Rigon M; Thibault V; Longuet M; Pol S; Blanc F; Pialoux G; Karras A; Bazin-Karra D; Cazorla C; Vittecoq D; Musset L; Decaux O; Ziza JM; Lambotte O; Cacoub P
    Ann Rheum Dis; 2014 May; 73(5):831-7. PubMed ID: 23606708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
    J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies.
    Fabrizi F; Dixit V; Messa P
    J Med Virol; 2013 Jun; 85(6):1019-27. PubMed ID: 23588727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies.
    Garini G; Allegri L; Vaglio A; Buzio C
    Ann Ital Med Int; 2005; 20(2):71-80. PubMed ID: 16052839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ
    Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C].
    Zhdanov KV; Gusev DA; Kozlov KV; Shishkin MK; Sukachev VS; Shakhmanov DM; Zhabrov SS
    Voen Med Zh; 2015 Apr; 336(4):44-9. PubMed ID: 26454938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
    Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
    Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic hepatitis C: improved cure rates with new approved medications].
    Grammatikos G; Vermehren J; Zeuzem S
    MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():65-9; quiz 70. PubMed ID: 22916428
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.
    Benstead TJ; Chalk CH; Parks NE
    Cochrane Database Syst Rev; 2014 Dec; (12):CD010404. PubMed ID: 25525951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C virus therapy to date.
    Foster G; Mathurin P
    Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simeprevir for the treatment of chronic hepatitis C.
    You DM; Pockros PJ
    Expert Opin Pharmacother; 2013 Dec; 14(18):2581-9. PubMed ID: 24138198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.